ClinicalTrials.gg
CompletedNCT05406570VT4HEMODUpdated Nov 20, 2026

Personalized Tidal Volume in ARDS (VT4HEMOD)

An interventional study of Standardized ventilation and Personalized ventilation in Acute Respiratory Distress Syndrome, sponsored by Hospices Civils de Lyon. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Hospices Civils de Lyon · Not applicable, Interventional, and Treatment

How we know

Updated Nov 20, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Respiratory Distress Syndrome by Hospices Civils de Lyon — 2 open to participants now, 2 under way, none of them phase 3. Respiratory Distress Syndrome · Hospices Civils de Lyon.

Enrollment
12th of 13
10 · median 31
Started
2022
the only one that year
No phase
13 of 15
1 open now
Registered
13th of 15
by date

Among the 15 studies in Respiratory Distress Syndrome by Hospices Civils de Lyon, this one is the 12th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2022, is one of 13 with no phase, and was the 13th registered.

Respiratory Distress Syndrome

1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.

Browse Respiratory Distress Syndrome studies →

Open to participants now

2 of the 15 studies in Respiratory Distress Syndrome by Hospices Civils de Lyon are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Respiratory Distress Syndrome by Hospices Civils de Lyon, or all of them as a file.
02

Study summary

Treatment of acute respiratory distress syndrome (ARDS) relies on invasive mechanical ventilation with supposedly protective settings (low tidal volume ventilation). Mortality of ARDS remains high in observational studies (40 to 50%). Approximately 30% of ARDS patients exhibit tidal hyperinflation despite low tidal volume ventilation, suggesting that personalization of tidal volume is required to improve ARDS prognostic. To date, reliable bedside tools to adjust tidal volume are lacking. Excessive tidal volume can be detected using computed tomography by quantification of tidal hyperinflation, but this technique is reserved to research studies and requires patient transport to imaging facility.

Mechanical ventilation generates cardio-pulmonary interaction, whose magnitude is influenced by tidal volume and respiratory system characteristics. Pulse pressure variation is a bedside tool with potential to quantify cardio-pulmonary interactions. Increasing tidal volume will decrease right ventricular preload and increase right ventricular afterload, hence maximizing cardio-pulmonary interactions.

The investigators hypothesize that pulse pressure variation might help to detect excessive tidal volume during a tidal volume challenge (i.e. stepwise increase in tidal volume)

03

Conditions studied

  • Acute Respiratory Distress Syndrome

Keywords

  • Acute Respiratory Distress Syndrome
  • cardiopulmonary interaction
  • tidal volume
  • computed tomography
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age greater then 18 years old
  2. ARDS according to the BERLIN definition with PaO2/FiO2 ratio ≤ 150 mm Hg
  3. invasive mechanical ventilation in volume controlled mode with tidal volume set to 6 ml/kg predicted body weight
  4. use of sedation and neuromuscular-blocking agents
  5. arterial catheter allowing computation of pulse contour cardiac output calibrated with thermodilution
  6. central venous catheter implanted in the superior vena cava territory
  7. esophageal balloon
  8. Computed tomography planned by attending physician

Exclusion criteria

Exclusion Criteria:

  1. Previous inclusion in current study
  2. Acute cor pulmonale
  3. ECMO
  4. Arterial pH \< 7.21 despite respiratory rate set to a maximum of 35/min
  5. Pneumothorax or bronchopleural fistula
  6. Decision to withdraw or withhold life sustaining treatment with 24 hours from inclusion
  7. of transport to imaging facility
  8. Intracranial hypertension
  9. Tricuspid or pulmonary mechanical valve
  10. Tricuspid or pulmonary infective endocarditis
  11. Pace maker with intracardiac leads
  12. Right ventricle tumor
  13. Complete left bundle block
  14. Intrathoracic metallic device
  15. Cardiac arrythmia
  16. Vesical pressure > 15 mm Hg
  17. Lower limb amputation
  18. Inferior vena cava thrombosis
  19. Patient under an exclusion period relative to participation to another clinical trial
  20. Patient under a legal protective measure
  21. Patient not affiliated to social security
  22. lac of patient/representative consent
  23. Pregnancy
  24. Breast feeding
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Active comparator
    Standardized tidal volume

    Ventilation with tidal volume 6 ml/kg

    Procedure: Standardized ventilation · Procedure: Personalized ventilation

  • Experimental
    Personalized tidal volume

    Ventilation with tidal volume aiming to minimize cardiopulmonary interactions as assessed by pulse pressure variation

    Procedure: Standardized ventilation · Procedure: Personalized ventilation

Interventions

  • ProcedureStandardized ventilation

    Patient will be ventilated with tidal volume 6 mL/kg predicted body weight (PBW) and positive end-expiratory pressure (PEEP) according to the PEEP-FiO2 table of the ARMA trial. A CT scan will be performed with this ventilatory setting and the patients will be switched to the other group

  • ProcedurePersonalized ventilation

    Patient will be ventilated with PEEP according to the PEEP-FiO2 table of the ARMA trial. Tidal volume will be selected as the tidal volume minimizing cardiopulmonary interactions as assessed on arterial pressure tracing, during a VT trial. A CT scan will be performed with this ventilatory setting and the patients will be switched to the other group.

06

What researchers measure

Primary outcomes

  1. Tidal hyperinflation

    Difference between hyperinflated volume in computed tomography images acquired at end-inspiration (defined by the volume of voxels with CT-number \< -900) and hyperinflated volume in computed tomography images acquired at end-expiration (defined by the volume of voxels with CT-number \< -900). This difference will be standardized to predicted body weight using the formula of the ARMA trial.

    Time frame: 5 minutes - This endpoint will be assessed 5 minutes after ventilatory adjustment

Secondary outcomes

  1. Tidal volume

    Standardized versus personalized tidal volume

    Time frame: 5 hours - This endpoint will be assessed through study completion (approximately 4-5 hours after study inclusion)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Jan 2026, 36 months.

Of 266 non-industry interventional studies with no phase under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's 36 months is above that.

Counting every sponsor, half of 273 studies reached it within 24 months; a quarter within 12 and three quarters within 42.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion Dec 2026 → Jan 2026 and completion Dec 2026 → Jan 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2022
First posted
Jun 6, 2022
StartActual
Dec 29, 2022
Primary completionActual
Jan 6, 2026was Dec 2026
CompletionActual
Jan 6, 2026was Dec 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 20, 2026
Primary completion
Dec 2026→Jan 6, 2026 (actual)
Nov 20, 2026
Study completion
Dec 2026→Jan 6, 2026 (actual)
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Recruiting→Completed
    Primary completion Dec 2026→Jan 6, 2026 (now actual)
    Study completion Dec 2026→Jan 6, 2026 (now actual)
    + 4 other changes: verification date, oversight details, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05406570
Responsible party
Sponsor
First posted
Jun 6, 2022
Start date
Dec 29, 2022
Primary completion
Jan 6, 2026
Completion
Jan 6, 2026
Last update
Nov 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion